Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 7/20 | 0.71 |
| ▸ | NPY2R | P49146 | 7/20 | 0.65 |
| ▸ | NPY4R | P50391 | 7/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.65 |
| ▸ | NPY1R | P25929 | 5/20 | 0.65 |
| ▸ | KDM1A | O60341 | 3/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.64 |
| ▸ | KDM5A | P29375 | 1/20 | 0.64 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599885 | 0.93 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31072603 | 0.92 | TFPI (0.72) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29533414 | 0.90 | TFPI (0.70) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31182515 | 0.89 | TFPI (0.68) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30186412 | 0.89 | EPHA2 (0.65) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31005079 | 0.89 | TFPI (0.67) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31105502 | 0.89 | NMUR2 (0.72) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30495778 | 0.89 | NPY2R (0.69) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29463778 | 0.88 | NPY2R (0.61) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29463786 | 0.88 | NPY2R (0.61) | TFPINPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| WO-2025229624-A2 | NEW CD38 INHIBITORS | NAPA THERAPEUTICS LIMITED (GB) | 2025-11-06 | — | — | WO | claimed |
| US-12161694-B2 | Methods and compositions for regulating innate lymphoid cell inflammatory responses | THE BROAD INSTITUTE, INC. (US) | 2024-12-10 | — | — | US | claimed |
| EP-4458834-A2 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-11-06 | — | — | EP | claimed |
| EP-4311832-A1 | PHOTOCAGED OREXIN-B | Universität Zürich (CH) | 2024-01-31 | — | — | EP | claimed |
| US-20230149516-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-05-18 | — | — | US | claimed |
| US-20230097988-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-03-30 | — | — | US | claimed |
| EP-4111201-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| EP-4110372-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | claimed |
| EP-4743083-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | Pleiogenix Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4199925-B1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026099243-A1 | MODIFIED AND UNMODIFIED PEPTIDYL-GLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL HYPOPERFUSION FOR THE IMPROVEMENT OF CEREBRAL BLOOD FLOW (CBF) | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | disclosed |
| US-12622978-B2 | Binding agents and uses thereof for central nervous system delivery | ARUNA BIO, INC. | 2026-05-12 | — | — | US | disclosed |
| WO-2022040058-A1 | CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022028572-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-20220023299-A1 | Combinations For Treatment Of NASH/NAFLD And Related Diseases | PFIZER INC. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2022020388-A1 | COMPOSITIONS AND METHODS RELATED TO ACTIVATABLE THERAPEUTIC AGENTS | AMUNIX PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622978-B2 | Binding agents and uses thereof for central nervous system delivery | BST2, SYNGR2, VAMP8 | TFPI 3703/4885NPY2R 1887/4885NPY4R 2899/4885 |
| US-11254660-B2 | Combinations for treatment of NASH/NAFLD and related diseases | FABP1, PPARG, GOT2 | TFPI 3878/4885NPY2R 1337/4885NPY4R 729/4885 |
| US-12161694-B2 | Methods and compositions for regulating innate lymphoid cell inflammatory responses | NMUR1, NMUR2, IL33 | TFPI 2191/4885NPY2R 160/4885NPY4R 375/4885 |
| US-20220023299-A1 | Combinations For Treatment Of NASH/NAFLD And Related Diseases | FABP1, PPARG, GOT2 | TFPI 3878/4885NPY2R 1337/4885NPY4R 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.